2. Signaling Pathways
  3. GPCR/G Protein
    Neuronal Signaling
  4. Opioid Receptor
  5. μ Opioid Receptor/MOR Isoform
  6. μ Opioid Receptor/MOR Antagonist

μ Opioid Receptor/MOR Antagonist

μ Opioid Receptor/MOR Antagonists (19):

Cat. No. Product Name Effect Purity
  • HY-114072
    J-113397
    		Antagonist
    J-113397 is the first potent and selective nonpeptidyl ORL1 receptor antagonist (Ki: cloned human ORL1=1.8 nM) without any agonistic effects on other opioid receptors.
  • HY-P1329A
    CTOP TFA
    		Antagonist 99.93%
    CTOP TFA is a potent and highly selective μ-opioid receptor antagonist.
  • HY-101011
    Naloxonazine dihydrochloride
    		Antagonist
    Naloxonazine dihydrochloride is a specific μ-opioid receptor antagonist with an IC50 of 5.4 nM.
  • HY-107748
    5'-Guanidinonaltrindole hydrochloride
    		Antagonist 98.65%
    5'-Guanidinonaltrindole (5'-GNTI) hydrochloride is a highly selective and potent κ-opioid receptor antagonist with a Ki of 0.18 nM for human κ-opioid receptor.
  • HY-P1335A
    CTAP TFA
    		Antagonist 99.56%
    CTAP TFA is a potent, highly selective, and BBB penetrant μ opioid receptor antagonist, with an IC50 of 3.5 nM.
  • HY-115066
    GSK1521498 free base
    		Antagonist 98.55%
    GSK1521498 free base is a potent and selective μ-opioid receptor (MOR) antagonist.
  • HY-76657A
    Alvimopan dihydrate
    		Antagonist 98.70%
    Alvimopan dihydrate (ADL 8-2698 dihydrate) is a potent, selective, orally active and reversible μ-opioid receptor antagonist, with an IC50 of 1.7 nM.
  • HY-76657
    Alvimopan monohydrate
    		Antagonist 99.18%
    Alvimopan monohydrate (ADL 8-2698 monohydrate) is a potent, selective, orally active and reversible μ-opioid receptor antagonist, with an IC50 of 1.7 nM.
  • HY-115066A
    GSK1521498 free base (hydrochloride)
    		Antagonist
    GSK1521498 free base (hydrochloride) is a potent and selective μ-opioid receptor (MOR) antagonist.
  • HY-P1335
    CTAP
    		Antagonist
    CTAP is a potent, highly selective, and BBB penetrant μ opioid receptor antagonist, with an IC50 of 3.5 nM.
  • HY-19627A
    Naldemedine tosylate
    		Antagonist
    Naldemedine (S-297995) tosylate is an orally active μ-opioid receptor antagonist (PAMORA).
  • HY-144609
    Mu opioid receptor antagonist 4
    		Antagonist
    Mu opioid receptor antagonist 4 (compound 31) is a potent and selective μ opioid receptor (MOR) antagonist with a Ki of 0.38 nM and an EC50 of 1.07 nM.
  • HY-118949
    LY255582
    		Antagonist
    LY255582 is a pan-opioid antagonist and has high affinity for mu, delta, and kappa receptors (Ki: 0.4 nM, 5.2, 2.0 nM respectively).
  • HY-144610
    Mu opioid receptor antagonist 5
    		Antagonist
    Mu opioid receptor antagonist 5 (compound NAP) is a selective and blood-brain barrier (BBB) penetrant μ opioid receptor (MOR) antagonist with an EC50 value of 1.14 nM and a Ki value of 0.37 nM.
  • HY-144608
    Mu opioid receptor antagonist 3
    		Antagonist
    Mu opioid receptor antagonist 3 (compound 26) is a potent and selective μ opioid receptor (MOR) antagonist with a Ki of 0.24 nM and an EC50 of 0.54 nM.
  • HY-144607
    Mu opioid receptor antagonist 2
    		Antagonist
    Mu opioid receptor antagonist 2 (compound 25) is a potent, selective and blood-brain barrier (BBB) penetrant μ opioid receptor (MOR) antagonist with a Ki of 0.37 nM and an EC50 of 0.44 nM.
  • HY-19902
    GSK1521498
    		Antagonist
    GSK1521498 is a potent and selective μ-opioid receptor (MOR) antagonist.
  • HY-144606
    Mu opioid receptor antagonist 1
    		Antagonist
    Mu opioid receptor antagonist 1 (compound 19) is a selective and orally active μ opioid receptor (MOR) ligand with an Ki value of 0.58 nM and an EC50 of 1.15 nM.
  • HY-A0118AS
    Naloxegol-d5 (oxalate)
    		Antagonist